FUNCTION Anti-wrinkle.

DEFINITION A novel approach in the research of active matrikines®: Palmitoylated tripeptide Lysyl-Histidyl-Glycine with a grafted proline on the lysine.

PROPERTIES MATRIXYL® Morphomics™ supports the reduction of vertical lines (frown lines, marionette lines, nasogenian fold) but also crow’s feet after 6 weeks, for a happier expression.

CHARACTERISTICS MATRIXYL® Morphomics™ influences cellular and dermal morphology by re-establishing and rebooting the skin connections between the fibroblast nucleus and the ECM.

POINT OF INTEREST Proteomics of Youth™ reveal the activation of longevigenes™ against signs of ageing.

APPLICATIONS Anti-ageing creams, serums, gels...

FORMULATION water soluble
Add in the formula between room temperature and 50°C.

RECOMMENDED USE LEVEL 2%

PATENT FR 3 029 782 - WO 2016 097 965

INCI NAME Water (Aqua) – Pentylene Glycol – Caprylyl Glycol – N-Prolyl Palmitoyl Tripeptide-56 Acetate

6 weeks to turn marionette lines into a smile
MATRIXYL® Morphomics™ reboots the connection between the nucleus and the ECM by ensuring the cytoskeleton integrity.

Matrix metalloproteinase-2 (MMP2)
Plasminogen activator inhibitor-1 (PAI-1)
Procollagen C-endopeptidase enhancer-1 (PCOLCE)
N-proteinase (ADAMTS1)
Procollagen gluco-galactosyl-transferase1 (COLGALT1)
Procollagen-lysin, 2-oxoglutarate 5-dioxygenase (PLOD1)
Prolyl 4-hydrolase subunit alpha-1 (P4HA1)
Protein disulfide isomerase (PDI)
Integrin α1
Integrin β1
Fibronectin
Actin
Cofilin
α-Actinin-1

Roughness (µm) .................... -9.9%
Deep wrinkles surface (%) . -26.6%
Mean depth (µm) ................. -13.5%
Main wrinkle volume (mm³) .. -16.5%
Wrinkle width angle (°) .......... +16.4%

CROW’S FEET
Instrumental evaluation of the crow’s feet by FOITS on 32 female panellists and on 20 male panellists.
Main wrinkle volume (mm³) . -16.5%/T0 up to -52%, -7.1%/placebo, p<0.07
Mean depth (µm) ................. -13.5%/T0 up to -44%, -7.3%/placebo, p<0.01
Deep wrinkles surface (%) . -26.6%/T0 up to -75%, -14.3%/placebo, p<0.06
Roughness (µm) ................. -9.9%/T0 up to -30%, -4.9%/placebo, p<0.05
Wrinkle width angle (°) .......... +16.4%/T0 up to +45%, +15.2%/placebo, p<0.01

Visible reduction of vertical lines
Evaluation of the vertical line perception by 5 expert judges on 34 female panellists.
MATRIXYL® Morphomics™ exerts a significantly perceivable effect on reducing vertical lines compared to the placebo, especially the frown lines.

Clinical Studies
2 female panels with mean age 64 and 58 years old and one male panel with mean age 59 years old. Twice daily application of a cream with 2% MATRIXYL® Morphomics™ on the face against placebo for 6 weeks.

Marionette lines
Instrumental evaluation of the marionette lines by FOITS on 26 female panellists.
Volume (mm³) .................... -22.7%/T0 up to -99%, -21.7%/placebo, p<0.08
Perimeter (mm) .................. -10.6%/T0 up to -92%, -9.6%/placebo, p<0.06

Frown lines
Instrumental evaluation of the frown lines by FOITS on 2x32 female panellists.
Volume (mm³) .................... -9.5%/T0 up to -65%, -9.2%/placebo, p<0.05
Perimeter (mm) .................. -7.1%/T0 up to -39%, -7.8%/placebo, p<0.05
Roughness (Sa in µm) .......... -5.8%/T0 up to -20%, -3.9%/placebo, p<0.07

sederma
20 rue du Chemin Vert
78612 Le Plessis-en-Yvelines cedex France
Tel.: +33 (0)1 34 84 10 10

Reproduction of all or part of this document without the express prior written consent of Sederma is strictly prohibited.